PathAI is still independent as of mid 2026, but Roche signed a definitive merger agreement on May 7, 2026 to acquire it for up to $1.05B ($750M upfront plus up to $300M in milestones), with closing expected H2 2026 pending regulatory review.

Is PathAI profitable?

PathAI has not disclosed profitability. The company states 260% revenue growth from 2020-2023 (as of an August 2025 release) but no net income or profitability figures have been made public, and it remains privately held pending the Roche acquisition.

Has PathAI had layoffs?

Yes. PathAI cut 87 jobs in July 2023 according to Becker's Hospital Review. Glassdoor reviews dated May 2026 continue to cite 'frequent layoffs' as an employee concern, suggesting recurring headcount strain even before the Roche deal.

Could AI replace PathAI's product?

PathAI's own product is an AI substitute for manual pathologist tasks like tumor detection and case triage, so it's a seller of AI-driven replacement rather than a target. FDA clearances for AISight Dx (as of May 2026) create a regulatory moat frontier AI labs haven't crossed.

Who is PathAI's biggest competitor?

PathAI competes against specialized AI pathology peers Paige, Proscia, and Owkin. Larger diagnostics incumbents Roche, Quest Diagnostics, and Labcorp have chosen to partner with or acquire PathAI rather than build competing AI pathology tools in-house, as shown by Roche's May 2026 acquisition.

What happens if the Roche-PathAI deal falls apart?

If Roche's $1.05B acquisition (announced May 7, 2026, expected to close H2 2026) terminates on antitrust or other grounds, PathAI reverts to an independent company competing against Paige, Proscia, and Owkin with a shrinking headcount and no clear path to cash-flow positive operations.

AI companies and labs · acquisition pending · United States

PathAI

pathai.com ↗

AI pathology company selling image analysis tools to labs and drug researchers.

Defensible for now

Assessed 21 July 2026 · Evidence as of 21 July 2026

Real protection, with named pressure against it.

On the recordSince 21 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: Roche merger agreement closes or falls through on regulatory review

The call

PathAI's product and clearances look protected inside Roche, but the deal, not the technology, now decides what happens to the team and the upside.

PathAI builds artificial intelligence software that helps doctors and labs analyze pathology slides and scans more accurately. The company has proven its technology works by getting approval from the FDA and building tools that fit into hospital workflows, which makes it genuinely hard for competitors or new AI models to replace overnight. But here is the big change: Roche is buying the company for over a billion dollars, which means your equity stakes will convert to fixed cash or stock in Roche instead of growing with a fast-moving startup, and the deal won't close until late 2026, so your job security depends entirely on whether Roche keeps your specific role after the merger completes.

Why

AI pressure: Paige, Proscia, Owkin. Rivals ship competing FDA-cleared pathology AI, but Roche deal pulls PathAI out of that fight for now. Could AI do the core job? Unlikely.

Bigger players: Roche Diagnostics. Roche agreed to buy PathAI for up to $1.05B, closing expected H2 2026 pending antitrust review. Could a giant copy it? No, they are blocked.

What protects it. FDA clearances, hospital workflow lock-in at Labcorp, Quest, MedStar, and now a signed Roche acquisition agreement.

What would change this call

Roche and PathAI deal closes or is blocked/withdrawn by H2 2026. Close confirms moat validation; failure reverts PathAI to standalone risk vs Paige, Proscia, Owkin.
Post-close headcount changes in PathAI's core product, regulatory, and clinical teams. Cuts to these functions vs G&A/commercial would signal integration erosion of the acquired capability.
PathAssist Derm advances from Breakthrough Device Designation to full FDA clearance. Progression shows regulatory moat still expanding independent of the Roche deal outcome.

Key numbers

$1.05B Roche deal, $750M upfront plus $300M milestones (2026-05-07)
~614 employees, down 27.4% from 2023 peak of 846 (2025-12-31)
87 employees laid off in one 2023 round (2023-07-26)

Named risks

Roche's $1.05B acquisition could terminate on antitrust or regulatory review before H2 2026 close. Severity: high
Post-close Roche integration may cut overlapping G&A or commercial roles versus core product teams. Severity: medium
History of layoffs (87 cut in July 2023, frequent layoffs cited in 2026 Glassdoor reviews) signals recurring internal strain. Severity: medium
Conflicting third-party revenue and headcount figures across trackers limit transparency into true company health. Severity: medium
PathAssist Derm holds only FDA Breakthrough Device Designation, not full clearance, as of March 2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Paige	contesting	Listed as direct AI digital pathology competitor per company comparison, 2026-07-19
Proscia	contesting	Direct competitor in AI-powered digital pathology software space, 2026-07-19
Owkin	contesting	Pitchbook-listed competitor set alongside Keen Eye in AI pathology, n.d.
Roche Diagnostics	gaining on	Chose to acquire PathAI for up to $1.05B rather than build competing AI in-house, 2026-05-07

Questions people ask

Who owns PathAI now?: PathAI is still independent as of mid 2026, but Roche signed a definitive merger agreement on May 7, 2026 to acquire it for up to $1.05B ($750M upfront plus up to $300M in milestones), with closing expected H2 2026 pending regulatory review.
Is PathAI profitable?: PathAI has not disclosed profitability. The company states 260% revenue growth from 2020-2023 (as of an August 2025 release) but no net income or profitability figures have been made public, and it remains privately held pending the Roche acquisition.
Has PathAI had layoffs?: Yes. PathAI cut 87 jobs in July 2023 according to Becker's Hospital Review. Glassdoor reviews dated May 2026 continue to cite 'frequent layoffs' as an employee concern, suggesting recurring headcount strain even before the Roche deal.
Could AI replace PathAI's product?: PathAI's own product is an AI substitute for manual pathologist tasks like tumor detection and case triage, so it's a seller of AI-driven replacement rather than a target. FDA clearances for AISight Dx (as of May 2026) create a regulatory moat frontier AI labs haven't crossed.
Who is PathAI's biggest competitor?: PathAI competes against specialized AI pathology peers Paige, Proscia, and Owkin. Larger diagnostics incumbents Roche, Quest Diagnostics, and Labcorp have chosen to partner with or acquire PathAI rather than build competing AI pathology tools in-house, as shown by Roche's May 2026 acquisition.
What happens if the Roche-PathAI deal falls apart?: If Roche's $1.05B acquisition (announced May 7, 2026, expected to close H2 2026) terminates on antitrust or other grounds, PathAI reverts to an independent company competing against Paige, Proscia, and Owkin with a shrinking headcount and no clear path to cash-flow positive operations.

Timeline

2026-05-13PathAI press releases list Labcorp nationwide AISight deployment and Brazil SUS collaboration
2026-05-11AISight Dx v2.20 release improves viewer usability and workflow efficiency
2026-05-07Roche signs definitive merger agreement to acquire PathAI for up to $1.05B
2026-04-07PathAI and MedStar Health announce multi-year deal covering 40+ pathologists
2026-04-06AIM-MASH becomes first AI tool with FDA qualification for MASH clinical trials
2026-03-03PathAI receives FDA Breakthrough Device Designation for PathAssist Derm
2025-08-04PathAI ranks #420 on Deloitte 2024 Technology Fast 500, down from #259 in 2023
2024Quest Diagnostics partnership deploys AISight and acquires PathAI's clinical lab business (Poplar Healthcare)
2023-07-26PathAI lays off 87 employees
2021PathAI closes $165M Series C round co-led by Kaiser Permanente

Revision history

21 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Broadcom Nvidia Marvell Technology